| Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study S Blach, NA Terrault, F Tacke, I Gamkrelidze, A Craxi, J Tanaka, I Waked, ... The Lancet Gastroenterology & Hepatology 7 (5), 396-415, 2022 | 439 | 2022 |
| Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study D Razavi-Shearer, I Gamkrelidze, C Pan, J Jia, T Berg, R Gray, YS Lim, ... The Lancet Gastroenterology & Hepatology 8 (10), 879-907, 2023 | 137 | 2023 |
| A Review of Non-Alcoholic Fatty Liver Disease in HIV-Infected Patients: The Next Big Thing? BJ van Welzen, T Mudrikova, A El Idrissi, AIM Hoepelman, JE Arends Infectious diseases and therapy, 1-18, 2019 | 80 | 2019 |
| Estimated glomerular filtration rate, albuminuria, and adverse outcomes: an individual-participant data meta-analysis LJ Appel, M Grams, M Woodward, K Harris, H Arima, J Chalmers, ... Jama 330 (13), 1266-1277, 2023 | 71 | 2023 |
| A highly virulent variant of HIV-1 circulating in the Netherlands C Wymant, D Bezemer, F Blanquart, L Ferretti, A Gall, M Hall, T Golubchik, ... Science 375 (6580), 540-545, 2022 | 65 | 2022 |
| HCV micro-elimination in individuals with HIV in the Netherlands 4 years after universal access to direct-acting antivirals: a retrospective cohort study C Smit, A Boyd, BJA Rijnders, TJW van de Laar, EM Leyten, WF Bierman, ... The Lancet HIV 8 (2), e96-e105, 2021 | 64 | 2021 |
| Changes in inflammatory and atherogenesis biomarkers with the 2-drug regimen dolutegravir plus lamivudine in antiretroviral therapy–experienced, virologically suppressed people … JM Llibre, PE Cahn, J Lo, TJ Barber, C Mussini, BJ van Welzen, ... Open Forum Infectious Diseases 9 (4), ofac068, 2022 | 28 | 2022 |
| Virological failure after switch to long-acting cabotegravir and rilpivirine injectable therapy: an in-depth analysis BJ van Welzen, SFL Van Lelyveld, G Ter Beest, JH Gisolf, SE Geerlings, ... Clinical Infectious Diseases, ciae016, 2024 | 23 | 2024 |
| Acute severe hepatitis outbreak in children: A perfect storm. What do we know, and what questions remain? PC Matthews, C Campbell, O Săndulescu, M Matičič, SM Ruta, ... Frontiers in pharmacology 13, 1062408, 2022 | 22 | 2022 |
| Decreased all-cause and liver-related mortality risk in HIV/hepatitis B virus coinfection coinciding with the introduction of tenofovir-containing combination antiretroviral … BJ van Welzen, C Smit, A Boyd, FI Lieveld, T Mudrikova, P Reiss, ... Open forum infectious diseases 7 (7), ofaa226, 2020 | 22 | 2020 |
| Hepatitis E virus as a causative agent of unexplained liver enzyme elevations in HIV-infected patients BJ van Welzen, FMV Lunel, F Meindertsma, AIM Hoepelman, JE Arends JAIDS Journal of Acquired Immune Deficiency Syndromes 60 (2), e65-e67, 2012 | 17 | 2012 |
| Lower Incidence of HIV-1 Blips Observed During Integrase Inhibitor–Based Combination Antiretroviral Therapy S Dijkstra, LM Hofstra, T Mudrikova, AMJ Wensing, PGA Oomen, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 89 (5), 575-582, 2022 | 13 | 2022 |
| Dual antiretroviral therapy—all quiet beneath the surface? BJ Van Welzen, PGA Oomen, AIM Hoepelman Frontiers in Immunology 12, 637910, 2021 | 13 | 2021 |
| Switching tenofovir disoproxil fumarate to tenofovir alafenamide results in a significant decline in parathyroid hormone levels: uncovering the mechanism of tenofovir … BJ Van Welzen, MAJ Thielen, T Mudrikova, JE Arends, AIM Hoepelman Aids 33 (9), 1531-1534, 2019 | 13 | 2019 |
| No increased risk of hepatotoxicity in long‐term use of nonnucleoside reverse transcriptase inhibitors in HIV‐infected patients BJ Van Welzen, T Mudrikova, JE Arends, AIM Hoepelman HIV medicine 13 (7), 448-452, 2012 | 13 | 2012 |
| The efficacy and tolerability of latency reversing agents in reactivating the HIV-1 reservoir in clinical studies: A systematic review Q Debrabander, KS Hensley, CK Psomas, W Bramer, T Mahmoudi, ... Journal of virus eradication, 100342, 2023 | 12 | 2023 |
| National medical specialty guidelines of HIV indicator conditions in Europe lack adequate HIV testing recommendations: a systematic guideline review CCE Jordans, M Vasylyev, C Rae, ML Jakobsen, A Vassilenko, N Dauby, ... Eurosurveillance 27 (48), 2200338, 2022 | 10 | 2022 |
| Twelve‐month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV: Real‐world insights from BICSTaR cohorts S Esser, J Brunetta, A Inciarte, I Levy, A D'Arminio Monforte, JS Lambert, ... HIV medicine 25 (4), 440-453, 2024 | 9 | 2024 |
| External validation of the PAGE-B score for HCC risk prediction in people living with HIV/HBV coinfection B Surial, AR Mena, M Roumet, A Limacher, C Smit, O Leleux, A Mocroft, ... Journal of hepatology 78 (5), 947-957, 2023 | 9 | 2023 |
| The perceived impact of an HIV cure by people living with HIV and key populations vulnerable to HIV in the Netherlands: A qualitative study KAGJ Romijnders, L de Groot, SCJM Vervoort, MGJ Basten, ... Journal of virus eradication 8 (1), 100066, 2022 | 8 | 2022 |
